#DiffuseLargeBCellLymphoma
August 30, 2026 at 1:53 AM
🩸 Facts about Diffuse Large B-Cell Lymphoma:

Treatment sequencing, chemotherapy-free options, bispecific antibodies, CNS relapse risk, elderly patients, and specialized DLBCL care.

#DLBCL #DiffuseLargeBCellLymphoma #Lymphoma #Hematology #HemeOnc #Oncology #MedicalEducation #MedEd #Cl
August 30, 2026 at 1:51 AM
August 26, 2026 at 11:58 PM
🩸 Facts about Diffuse Large B-Cell Lymphoma:

EPCORE NHL-2, bispecific + ADC combinations, ECHELON-3, polatuzumab vedotin, and loncastuximab tesirine, including key trial results and treatment advances in relapsed/refractory disease.

#DLBCL #DiffuseLargeBCellLymphoma #Lymphoma #HemeOnc #MedEd
August 26, 2026 at 11:54 PM
August 25, 2026 at 12:45 AM
🩸 Facts about Diffuse Large B-Cell Lymphoma:

Second-line and third-line treatment options, CAR-T resistance mechanisms, post-CAR-T outcomes, bispecific antibodies, Mosun-Pola and Pola-R-GemOx, and STARGLO trial results.

#DLBCL #DiffuseLargeBCellLymphoma #Lymphoma #Hematology #MedicalEducation
August 25, 2026 at 12:43 AM
August 20, 2026 at 4:32 AM
August 18, 2026 at 4:43 AM
🩸Facts about Diffuse Large B-Cell Lymphoma:

Metabolic tumor volume, circulating tumor DNA, molecular residual disease, pola-R-CHP, and POLARIX trial outcomes.

#DLBCL #DiffuseLargeBCellLymphoma #Lymphoma #Hematology #HemeOnc #Oncology #MedicalEducation #MedEd #ClinicalHematology #HemeHub
August 18, 2026 at 4:39 AM
🩸Join us for a live webinar with Sairah Ahmed, MD, and Elif Yilmaz, MD, on #DLBCL, exploring diagnosis, treatment strategies, and patient management through case-based insights.

⮕ Register: hemehub.org/live-webinars
⮕ Submit your cases: hemehub.org/case-submiss...

#HemeHub #Lymphoma #Hematology
August 18, 2026 at 4:36 AM
🎯💭Today’s questions!

Swipe to see the answers and explanations!

#DLBCL #DiffuseLargeBCellLymphoma #Lymphoma #Hematology #HemeOnc #Oncology #MedicalEducation #MedEd #ClinicalHematology #HemeHub
August 15, 2026 at 7:23 PM
🩸Facts about Diffuse Large B-Cell Lymphoma:

Genetic classification, clinical risk assessment, and PET/CT-based evaluation continue to refine prognosis and treatment response in DLBCL.

#DLBCL #DiffuseLargeBCellLymphoma #Lymphoma #Hematology #HemeOnc #Oncology #MedicalEducation #MedEd #HemeHub
August 15, 2026 at 7:21 PM
🩸Join us for a live webinar with Sairah Ahmed, MD, and Elif Yilmaz, MD, on #DLBCL, exploring diagnosis, treatment strategies, and patient management through case-based insights.

⮕ Register: hemehub.org/live-webinars
⮕ Submit your cases: hemehub.org/case-submiss...

#HemeHub #Lymphoma #Hematology
August 15, 2026 at 7:15 PM
August 11, 2026 at 2:48 AM
🩸 Facts about Diffuse Large B-Cell Lymphoma:

MYC rearrangements, double-hit/triple-hit lymphoma, double expressor status, CD5+ DLBCL, and genetic subtypes that further refine prognosis.

#DLBCL #DiffuseLargeBCellLymphoma #DoubleHitLymphoma #MYC #BCL2 #BCL6 #Oncology #ClinicalHematology #HemeHub
August 11, 2026 at 2:43 AM
August 6, 2026 at 9:27 PM
🩸 Facts about #DLBCL:

Disease prevalence, WHO 2024 classification, cell-of-origin subtypes, gene expression profiling, and diagnostic approaches.

#DiffuseLargeBCellLymphoma #Lymphoma #Pathology #Hematology #HemeOnc #Oncology #MedicalEducation #MedEd #ClinicalHematology #HemeHub
August 6, 2026 at 9:27 PM
In this study, researchers synthesized 10 pyrrolidone-based compounds & identified compound 7 as a promising #therapeutic candidate, as it induced #Apoptosis and exhibited potent #antitumor activity against #DiffuseLargeBCellLymphoma. #medsky

Read: link.springer.com/article/10.1...
November 10, 2025 at 5:00 AM
📊 Research Summary: In a phase 3 trial, adding tucidinostat to standard immunochemotherapy improved event-free survival in patients with MYC/BCL2 double-expressor #DiffuseLargeBCellLymphoma.

ja.ma/42KX54a
May 22, 2026 at 1:00 PM
Tucidinostat plus standard therapy increased complete response rates in MYC/BCL2 double-expressor #DiffuseLargeBCellLymphoma, with higher but manageable toxicity compared with standard treatment alone.

ja.ma/4uUDZ7u
May 22, 2026 at 12:00 PM
💬 Editorial: Epigenetic modulation with tucidinostat represents a promising approach to improve response and event-free survival in high-risk #DiffuseLargeBCellLymphoma treated with standard immunochemotherapy.

ja.ma/4us7cXV
May 22, 2026 at 11:00 AM
💬 Editorial: Epigenetic modulation with tucidinostat represents a promising approach to improve response and event-free survival in high-risk #DiffuseLargeBCellLymphoma treated with standard immunochemotherapy.

ja.ma/3QFeEzH
April 22, 2026 at 3:25 PM
📊 Research Summary: In a phase 3 trial, adding tucidinostat to standard immunochemotherapy improved event-free survival in patients with MYC/BCL2 double-expressor #DiffuseLargeBCellLymphoma.

ja.ma/41RTvET
April 22, 2026 at 3:20 PM
Tucidinostat plus standard therapy increased complete response rates in MYC/BCL2 double-expressor #DiffuseLargeBCellLymphoma, with higher but manageable toxicity compared with standard treatment alone.

ja.ma/4vLycT1
April 22, 2026 at 3:15 PM